USPTO Examiner ROONEY NORA MAUREEN - Art Unit 1641

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18977144NOVEL ANTIGEN BINDING MOLECULE FORMATSDecember 2024April 2025Allow410NoNo
18664070BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLSMay 2024March 2025Allow1020NoNo
18664091BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLSMay 2024December 2024Allow710NoNo
18640981NOVEL ANTIGEN BINDING MOLECULE FORMATSApril 2024February 2025Allow1011YesNo
18408386NUCLEIC ACIDS, VECTORS, AND CELLS THAT ENCODE ANTI-SP17 ANTIBODIES AND OTHER SP17 BINDING PROTEINSJanuary 2024October 2024Allow930NoNo
18395074IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOFDecember 2023April 2025Abandon1510NoNo
18494454VARIANT IgG FC POLYPEPTIDES AND USES THEREOFOctober 2023March 2024Allow401NoNo
18376135NANOEMULSION COMPOSITIONS FOR PREVENTING, SUPPRESSING OR ELIMINATING ALLERGIC AND INFLAMMATORY DISEASEOctober 2023May 2025Allow1910YesNo
18469961HLA BINDING VACCINE MOIETIES AND USES THEREOFSeptember 2023March 2025Allow1820NoNo
18469947NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND BCMA VARIANTS WITH FC-ENGINEERINGSeptember 2023August 2024Allow1111NoNo
18462987SOYBEAN ALLERGY ANTIGENSeptember 2023June 2025Allow2121NoNo
18331280Antibodies that Specifically Bind PD-1 and Methods of UseJune 2023November 2024Allow1810NoNo
18318871NOVEL ANTIGEN BINDING MOLECULE FORMATSMay 2023December 2023Allow710NoNo
18308338IL-21 POLYPEPTIDES AND TARGETED CONSTRUCTSApril 2023December 2024Allow2022YesNo
18303769CHIMERIC CANINE ANTI-CD20 ANTIBODYApril 2023September 2024Allow1720NoNo
18164442AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USEFebruary 2023June 2023Allow500NoNo
18160745Antibodies That Bind Human Cannabinoid 1 (CB1) ReceptorJanuary 2023November 2024Abandon2210NoNo
18018444IL23 RECEPTOR SYNTHETIC CYTOKINES AND METHODS OF USEJanuary 2023April 2025Abandon2631NoNo
18101601PD1-CD70 FUSION PROTEIN AND METHODS OF USE THEREOFJanuary 2023December 2024Abandon2301NoNo
18006484IFNGR BINDING SYNTHETIC CYTOKINES AND METHODS OF USEJanuary 2023June 2024Allow1621NoNo
18067504CD33-Binding Polypeptides and Uses ThereofDecember 2022May 2024Allow1700NoNo
18063896METHOD OF INDUCING TOLERANCE TO AN ALLERGENDecember 2022May 2025Abandon2920NoNo
17980397COMBINATIONS FOR ALLERGY THERAPYNovember 2022February 2024Abandon1621NoNo
18050993Therapeutic Anti-IgE Antibodies and Methods and Compositions ThereofOctober 2022April 2025Abandon2901NoNo
17921355PREPARATION AND APPLICATION OF AN INTACT RECOMBINANT ANTIBODY SPECIFIC TO CLOTHIANIDIN BASED ON THE IDENTIFIED VARIABLE REGION SEQUENCEOctober 2022November 2023Allow1320NoNo
17945504Immunotherapy For The Treatment Of Allergic DiseaseSeptember 2022September 2024Abandon2410NoNo
17891757MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAMEAugust 2022April 2025Allow3220YesNo
17887144BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENTAugust 2022September 2024Abandon2510NoNo
17877432ANTIBODIES THAT BIND HUMAN CANNABINOID 1 (CB1) RECEPTORJuly 2022May 2025Abandon3420YesNo
17858112PROCESS FOR OBTAINING ANTIBODIESJuly 2022December 2024Allow2920NoNo
17848808FC VARIANTS WITH REDUCED EFFECTOR FUNCTIONJune 2022October 2024Abandon2810NoNo
17834237Anti-PD-1 Antibodies and Uses ThereofJune 2022October 2023Allow1600YesNo
17752639METHODS OF ORAL IMMUNOTHERAPYMay 2022May 2025Allow3521YesNo
17736859METHODS OF TREATING AN ALLERGY WITH ALLERGEN-SPECIFIC MONOCLONAL ANTIBODIESMay 2022March 2024Abandon2210NoNo
17714507ANTI-ALLERGEN ANTIBODIESApril 2022January 2025Allow3410NoNo
17707243RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN (RIVIG) COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND USEMarch 2022June 2023Allow1500YesNo
17672571NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOFFebruary 2022January 2024Allow2300YesNo
17648242METHODS OF TREATING KAWASAKI DISEASEJanuary 2022May 2024Allow2810NoNo
17510772PEANUT HYPOALLERGENIC FORMULATIONS FOR DETERMINING THE RISK OF ANAPHYLAXISOctober 2021May 2024Abandon3011NoNo
17501305IMMUNE MODULATIONOctober 2021August 2024Abandon3410NoNo
17500418HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOFOctober 2021November 2024Allow3711NoNo
17500794ANTIBODIES TO OXIDATION-SPECIFIC EPITOPESOctober 2021March 2025Allow4120YesNo
17498512TREATMENT OF CANCER USING A CEA CD3 BISPECIFIC ANTIBODY AND A WNT SIGNALING INHIBITOROctober 2021March 2025Abandon4101NoNo
17601628COMBINATION OF SYNTHETIC PEPTIDES WITH AFFINITY TO THE TGF-� RECEPTOR AND WITH AFFINITY TO THE IL-10 RECEPTOR, PHARMACEUTICAL COMPOSITION AND THEIR USE AS IMMUNOMODULATORS IN THE TREATMENT OF AUTOIMMUNE, INFLAMMATORY OR ALLERGIC DISEASESOctober 2021June 2025Abandon4501NoNo
17601359METHODS OF DEPLETING DISEASE CAUSING AGENTS VIA ANTIBODY TARGETED PHAGOCYTOSISOctober 2021December 2024Abandon3801NoNo
17438702Manufacturing Methods for Producing Anti-TNF Antibody CompositionsSeptember 2021February 2024Allow2910NoNo
17471804ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOFSeptember 2021December 2023Allow2710NoNo
17438209NON-CONSENSUS GLYCOSYLATION OF BISPECIFIC ANTIBODIESSeptember 2021November 2024Abandon3910NoNo
17432705MODIFIED FC FRAGMENT, ANTIBODY COMPRISING SAME, AND APPLICATION THEREOFAugust 2021February 2025Allow4251YesNo
17399871CONDITIONING REGIMENS AND METHODS FOR INDUCING MIXED CHIMERISMAugust 2021January 2024Allow2920NoNo
17384628MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAMEJuly 2021January 2025Abandon4221YesNo
17374519NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOFJuly 2021December 2023Allow2910NoNo
17368366NANOEMULSION COMPOSITIONS FOR PREVENTING, SUPPRESSING OR ELIMINATING ALLERGIC AND INFLAMMATORY DISEASEJuly 2021June 2023Allow2410NoNo
17364299METHODS OF TREATING ALLERGY USING ANTI-BET V 1 ANTIBODIESJune 2021September 2023Allow2720NoNo
17414265ANTIGEN BINDING FORMATS FOR RECEPTOR COMPLEXESJune 2021December 2024Abandon4201NoNo
17298104METHODS FOR MAKING MIXED ALLERGEN COMPOSITIONSMay 2021September 2024Abandon4001NoNo
17297796ANTIBODY COMPRISING A GLUTAMINE-CONTAINING LIGHT CHAIN C-TERMINAL EXTENSION, CONJUGATES THEREOF, AND METHODS AND USESMay 2021December 2024Allow4310NoNo
17303268METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKING GALECTIN-3May 2021December 2024Allow4341YesNo
17325268MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOFMay 2021December 2023Allow3101NoNo
17315547VARIABLE REGIONS FOR NKP46 BINDING PROTEINSMay 2021September 2023Allow2901YesNo
17243372ANTI-PD-L1 ANTIBODIESApril 2021September 2024Allow4021NoNo
17285884RAPID CELL ISOLATION AND RECOVERY USING HOLLOW GLASS MICROSPHERES COATED WITH BIODEGRADABLE NANOSTRUCTURED FILMSApril 2021June 2025Allow5021NoNo
17231544MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAMEApril 2021January 2025Abandon4521YesNo
17282781HER2-BINDING TETRAMERIC POLYPEPTIDESApril 2021June 2025Abandon5001NoNo
17279958METHODS FOR DETECTING HOOK EFFECT(S) ASSOCIATED WITH ANAYLTE(S) OF INTEREST DURING OR RESULTING FROM THE CONDUCTANCE OF DIAGNOSTIC ASSAY(S)March 2021February 2025Allow4710NoNo
17278164ANTI-IgE ANTIBODY SPECIFICALLY BINDING TO MEMBRANE-BOUND IgE ANTIBODY OF IgE ANTIBODY-PRODUCING B CELLS AND METHOD FOR DIAGNOSING AND TREATING ALLERGIC SYMPTOMS USING THE SAMEMarch 2021January 2025Allow4611NoNo
17200374NOVEL ANTI-PD-L1 ANTIBODIESMarch 2021August 2024Allow4121YesNo
17147699METHOD AND MEANS FOR DIAGNOSING AND TREATING ALLERGYJanuary 2021March 2024Allow3820YesYes
17259271COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CTLA-4January 2021September 2024Abandon4401NoNo
17259067COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO PD-L1January 2021September 2024Abandon4501NoNo
17142825DIAGNOSTIC TESTS AND METHODS FOR ASSESSING SAFETY, EFFICACY OR OUTCOME OF ALLERGEN-SPECIFIC IMMUNOTHERAPY (SIT)January 2021February 2024Abandon3820NoNo
17127688ANTI-C5a RECEPTOR ANTIBODIESDecember 2020February 2024Abandon3821NoNo
17056460Biomarkers for improving nutrion for infants at riskNovember 2020September 2024Abandon4610NoNo
17053784LAMP CONSTRUCTS COMPRISING ALLERGENSNovember 2020January 2025Allow5131YesNo
17070129Anti-CTLA-4 Antibodies and Uses ThereofOctober 2020February 2024Allow4020YesNo
16980607METABOLIC ENZYME ACTIVITY AND DISULFIDE BOND REDUCTION DURING PROTEIN PRODUCTIONSeptember 2020February 2025Allow5321NoNo
16987487NOVEL ANTIGEN BINDING MOLECULE FORMATSAugust 2020September 2024Allow4911YesNo
16984946ANTI-KIT ANTIBODIES AND USES THEREOFAugust 2020September 2023Allow3711NoNo
16961418Modified Cell Expansion and Uses ThereofJuly 2020November 2024Abandon5211NoNo
16958072ANTIBODIES AND ASSAYS FOR CCL14June 2020September 2023Allow3911YesNo
16902518A B Cell Depleting Agent for the Treatment of AtherosclerosisJune 2020March 2024Allow4550NoNo
16770467MULTISPECIFIC MOLECULES AND USES THEREOFJune 2020March 2025Abandon5831YesNo
16842675PEANUT FORMULATIONS AND USES THEREOFApril 2020February 2024Allow4640YesNo
16646279IDENTIFICATION AND MONITORING OF IMMUNOGLOBULIN J CHAINSMarch 2020June 2023Allow4020NoNo
16611859METHODS OF PURIFYING ANTIBODIESNovember 2019March 2024Allow5221YesNo
16664849METHODS OF POPULATING PRECIPITATED PARTICLES OF A MODIFIED OR SYNTHESIZED SUBSTANCE IN A TISSUEOctober 2019April 2024Abandon5321NoYes
16608239ALLERGY ANTIGEN AND EPITOPE THEREOFOctober 2019January 2024Abandon5122NoNo
16606656METHOD OF PREPARING pH-DEPENDENT ANTIBODIESOctober 2019March 2024Allow5321NoNo
16495552METHODS AND COMPOSITIONS FOR INDUCIBLE EXTRACELLULAR MEMBRANE CAPTURE OF MONOCLONAL IMMUNOGLOBULINS SECRETED BY HYBRIDOMASSeptember 2019December 2023Allow5121NoNo
16542198PEANUT ORAL IMMUNOTHERAPY WITH MAINTENANCE DOSEAugust 2019June 2025Allow6071NoNo
16428411DIFFERENTIAL DIAGNOSIS OF ECZEMA AND PSORIASISMay 2019February 2024Allow5741NoNo
16417946Peptides And Methods For Detecting Peanut AllergiesMay 2019June 2025Abandon6042NoNo
16349965BISPECIFIC OR BIPARATOPIC ANTIGEN BINDING PROTEINS AND USES THEREOFMay 2019October 2024Abandon6011NoNo
16343162ADAPTER CHIMERIC ANTIGEN RECEPTOR EXPRESSING CELLS FOR TARGETING OF MULTIPLE ANTIGENSApril 2019November 2023Abandon5521NoNo
16335022POLYPEPTIDE CONSTRUCT COMPRISING FRAGMENTS OF ALLERGENSMarch 2019September 2023Allow5431YesNo
16325144ANTI-PD-1 ANTIBODYFebruary 2019November 2024Abandon6090YesYes
16311434ANTI-PD-L1 AND IL-2 CYTOKINESDecember 2018May 2023Allow5221YesYes
16309453FISH ALLERGY ANTIGENDecember 2018February 2024Abandon6051YesNo
16081032SOYBEAN ALLERGY ANTIGENAugust 2018December 2023Abandon6051YesNo
15682247Methods Of Using Chimeric Receptors To Identify Autoimmune DiseaseAugust 2017April 2018Allow710NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ROONEY, NORA MAUREEN.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
2
(50.0%)
Examiner Reversed
2
(50.0%)
Reversal Percentile
69.3%
Higher than average

What This Means

With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
30
Allowed After Appeal Filing
12
(40.0%)
Not Allowed After Appeal Filing
18
(60.0%)
Filing Benefit Percentile
62.6%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner ROONEY, NORA MAUREEN - Prosecution Strategy Guide

Executive Summary

Examiner ROONEY, NORA MAUREEN works in Art Unit 1641 and has examined 206 patent applications in our dataset. With an allowance rate of 80.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner ROONEY, NORA MAUREEN's allowance rate of 80.1% places them in the 43% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by ROONEY, NORA MAUREEN receive 2.45 office actions before reaching final disposition. This places the examiner in the 84% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ROONEY, NORA MAUREEN is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +17.0% benefit to allowance rate for applications examined by ROONEY, NORA MAUREEN. This interview benefit is in the 62% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.8% of applications are subsequently allowed. This success rate is in the 24% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 47.6% of cases where such amendments are filed. This entry rate is in the 67% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 86.7% of appeals filed. This is in the 77% percentile among all examiners. Of these withdrawals, 76.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 55.6% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 7.3% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.6% of allowed cases (in the 74% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.